| |  Online-Ressource |
|---|
| Verfasst von: | Krämer, Isabelle [VerfasserIn]  |
|---|
| | Hensel, Manfred [VerfasserIn] |
|---|
| | Rieger, Michael [VerfasserIn] |
|---|
| | Horstmann, Kristin [VerfasserIn] |
|---|
| | Hiddemann, Wolfgang [VerfasserIn] |
|---|
| | Dreyling, Martin [VerfasserIn] |
|---|
| | Koniczek, Silvia [VerfasserIn] |
|---|
| | Witzens-Harig, Mathias [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| Titel: | Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström’s macroglobulinemia |
|---|
| Verf.angabe: | Isabelle Herth, Manfred Hensel, Michael Rieger, Kristin Horstmann, Wolfgang Hiddemann, Martin Dreyling, Silvia Koniczek, Mathias Witzens-Harig, Anthony D. Ho |
|---|
| Jahr: | 2015 |
|---|
| Jahr des Originals: | 2014 |
|---|
| Umfang: | 6 S. |
|---|
| Fussnoten: | Published online: 25 Jun 2014 ; Gesehen am 31.08.2020 |
|---|
| Titel Quelle: | Enthalten in: Leukemia and lymphoma |
|---|
| Ort Quelle: | London [u.a.] : Taylor & Francis Group, 1989 |
|---|
| Jahr Quelle: | 2015 |
|---|
| Band/Heft Quelle: | 56(2015), 1, Seite 97-102 |
|---|
| ISSN Quelle: | 1029-2403 |
|---|
| Abstract: | Waldenström’s macroglobulinemia (WM) is an indolent lym phomaand is responsive to therapy regimens containing alkylating agents, purine analogs and rituximab if treatment becomes necessary. We initiated a multicenter phase II trial to determine the safety and efficacy of a regimen containing pentostatin, cyclophosphamide and rituximab (PER) in patients with WM. Between May 2005 and December 2010, 25 patients with WM were included in the study. Twenty-one patients received PER as first-line therapy. In these patients, 2-year progression-free survival was 83.6% and 2-year overall survival was 100%. Thirteen patients (52%) received R maintenance therapy. In these patients, the 2-year progression-free survival was 91.67% and 2-year overall survival was 100%. We have provided evidence that PER is a safe and effective regimen for WM. Although R maintenance therapy after PER seemed to induce a better long-term outcome, this study was not powered to address this issue. |
|---|
| DOI: | doi:10.3109/10428194.2014.911869 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3109/10428194.2014.911869 |
|---|
| | DOI: https://doi.org/10.3109/10428194.2014.911869 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | cyclophosphamide |
|---|
| | maintenance therapy |
|---|
| | pentostatin |
|---|
| | rituximab |
|---|
| | Waldenström macroglobulinemia |
|---|
| K10plus-PPN: | 1728045622 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström’s macroglobulinemia / Krämer, Isabelle [VerfasserIn]; 2015 (Online-Ressource)
